Inimmune
Inimmue: A cutting-edge biotech firm, pioneering next-gen immunotherapeutics.
Founded
2016Inimmue: A cutting-edge biotech firm, pioneering next-gen immunotherapeutics.
Inimmune is a biotechnology company founded by pharmaceutical industry veterans and headquartered in Missoula, Montana. The core mission of Inimmune is to harness the immune system to develop next-generation immunotherapeutics aimed at treating various diseases. The company focuses on creating innovative therapies that enhance the body's natural immune response, with a particular emphasis on cancer and infectious diseases. Their product pipeline includes advanced programs and discovery initiatives designed to bring cutting-edge treatments to market.
Notable figures affiliated with Inimmune include experienced professionals from the pharmaceutical industry who contribute to the company's strategic direction and scientific advancements. The company has garnered attention from investors interested in pioneering immunotherapy solutions. Key achievements include the development of promising therapeutic candidates and establishing strategic partnerships to accelerate research and development. Inimmune's impact lies in its potential to revolutionize treatment paradigms through innovative immunotherapeutic approaches, offering hope for more effective disease management.
Companies similar to Inimmune include INmune Bio, Immunome, ImmunityBio and Inmagene Biopharmaceuticals.
Inimmune was founded in 2016.
Inimmune's headquarters is located in Missoula, MT, US.
Inimmune's most recent funding round was for $22M (USD) in July 2020.
As of Jul 9, 2020, Inimmune has disclosed funding of $22.6M (USD). Undisclosed round amounts are excluded.
Inimmune has 15 employees as of Feb 5, 2024.
inmagenebio.com
